BPC-157 & TB-500 Peptide Strips for Recovery Support: Wolverine Stack Launched

Neuvera launches the Wolverine Stack, combining BPC-157 and TB-500 peptides in a dissolving oral strip format to support natural recovery, amid growing research interest and recent U.S. regulatory review of both peptides.

Hanover, United States, September 21, 2026 /PressCable/ -- Neuvera has launched BPC-157 + TB-500 oral dissolving strips, delivering two research peptides known as the “Wolverine Stack” in a pre-measured, needle-free format. Designed for individuals and athletes focused on recovery and resilience, the strips dissolve within seconds and require no water or refrigeration, making them easy to incorporate into daily routines.

More information is available at https://neuveralife.com/products/bpc-157-tb-500

The Wolverine Stack refers to the pairing of BPC-157 and TB-500, a nickname inspired by the fictional character’s rapid healing abilities. BPC-157 is a synthetic peptide studied in preclinical research for tissue repair and related signaling, while TB-500, a fragment of thymosin beta-4, is studied for cell movement and tissue remodeling. Human evidence for these uses remains limited.

The combination has drawn attention following recent U.S. regulatory developments. In July 2026, the FDA’s advisory committee recommended adding both peptides to the 503A Bulks List. Easing restrictions and a 33-fold surge in documented interest have also highlighted the growing focus on BPC-157 and TB-500.

Neuvera notes that injectable peptide use typically requires sterile preparation, proper handling, and needle disposal. However, its oral dissolving strips provide both peptides in a single, needle-free format. Each strip contains 500 micrograms of BPC-157 and 500 micrograms of TB-500 and dissolves in seconds against the roof of the mouth. According to the company, its RapidRelease technology uses enzymes, including Beta-Cyclodextrin and Sodium Caprate, to enhance mucosal absorption and move peptide molecules into systemic circulation while bypassing first-pass digestion.

The company reports a 92.5 percent absorption rate and a 5-15-minute onset for its RapidRelease technology, noting that these figures were validated using Glutathione, the largest molecule in its product line.

Neuvera adds that the strips do not require cold storage and are available in 30-day and 90-day supply options.

New Jersey-based Neuvera, an AI-driven biotech company, develops precision-formulated wellness products, including non-injectable formats such as sublingual strips, lotions, and sprays, all formulated by scientists. Its products are manufactured in a U.S. facility certified to cGMP and NSF standards, with transparent ingredient and research information. The company notes that these products are not intended to diagnose, treat, cure, or prevent any disease.

Additional information about BPC-157 + TB-500 and Neuvera’s product range is available at https://neuveralife.com/

Contact Info:
Name: Rachel Candler
Email: Send Email
Organization: Neuvera
Address: 3 Wing Dr Cedar Knolls, Hanover, New Jersey 07927, United States
Website: https://neuveralife.com/

Source: PressCable

Release ID: 89203961

In case of identifying any errors, concerns, or inconsistencies within the content shared in this press release that necessitate action or if you require assistance with a press release takedown, we strongly urge you to notify us promptly by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team is committed to addressing your concerns within 8 hours by taking necessary actions diligently to rectify any identified issues or supporting you with the removal process. Delivering accurate and reliable information remains our top priority.